Predict your next investment

Venture Capital

See what CB Insights has to offer

Investments

26

Portfolio Exits

9

Funds

2

About Cogene Ventures

Cogene Ventures is a life-sciences and medical-technology venture capital firm with an investment focus on biopharmaceuticals and biotechnology platforms that enable better, faster and cheaper therapeutic drug discovery. Other areas of investment focus include bio-nanotechnology, therapeutic medical devices and health-care IT/software. With approximately $50 million under management, Cogene's investments range in size from $200,000 to $5 million with two portfolio companies, Lexicon Genetics (NASDAQ: LEXG) and Informax (NASDAQ: INMX), currently trading in the public markets. The president and CEO of Cogene Biotech Ventures is Dr. C. Thomas Caskey, the former SVP of Research at Merck, a member of the National Academy of Sciences and one of the nation's most respected experts on genomics.

Cogene Ventures Headquarter Location

4400 Post Oak Parkway Suite 1400

Houston, Texas, 77027,

United States

713-336-7858

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Cogene Ventures Investments

26 Investments

Cogene Ventures has made 26 investments. Their latest investment was in MacroGenics as part of their Series E on January 1, 2011.

CBI Logo

Cogene Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/31/2011

Series E

MacroGenics

$12.02M

No

3/6/2010

Series C

Odyssey Thera

$3.5M

No

10/13/2006

Unattributed VC - II

MedServe

$70M

No

10/17/2005

Series B

Subscribe to see more

$99M

Subscribe to see more

0

10/13/2005

Series D

Subscribe to see more

$99M

Subscribe to see more

0

Date

1/31/2011

3/6/2010

10/13/2006

10/17/2005

10/13/2005

Round

Series E

Series C

Unattributed VC - II

Series B

Series D

Company

MacroGenics

Odyssey Thera

MedServe

Subscribe to see more

Subscribe to see more

Amount

$12.02M

$3.5M

$70M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

0

0

Cogene Ventures Portfolio Exits

9 Portfolio Exits

Cogene Ventures has 9 portfolio exits. Their latest portfolio exit was Helsinn on August 06, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/6/2021

Acquired

$99M

2

10/10/2013

IPO

Subscribe to see more

$99M

Subscribe to see more

10

5/14/2009

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

7/22/2008

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

6/11/2007

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/6/2021

10/10/2013

5/14/2009

7/22/2008

6/11/2007

Exit

Acquired

IPO

Acquired

Acquired

Reverse Merger

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

0

10

Cogene Ventures Fund History

2 Fund Histories

Cogene Ventures has 2 funds, including Cogene Biotech Ventures II LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

10/31/2004

Cogene Biotech Ventures II LP

Late-Stage Venture Capital

Closed

$157M

1

6/1/2000

Cogene Biotech Ventures LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

10/31/2004

6/1/2000

Fund

Cogene Biotech Ventures II LP

Cogene Biotech Ventures LP

Fund Type

Late-Stage Venture Capital

Subscribe to see more

Status

Closed

Subscribe to see more

Amount

$157M

$99M

Sources

1

10

Cogene Ventures Team

6 Team Members

Cogene Ventures has 6 team members, including current Chief Financial Officer, Kathy Mattina.

Name

Work History

Title

Status

Kathy Mattina

Chief Financial Officer

Current

M. Robert Dussler

Managing Director

Current

Thomas C. Caskey

Chief Executive Officer

Former

Fahim Samaha

Chief Executive Officer

Former

Scott E Schwinger

Chief Financial Officer

Former

Name

Kathy Mattina

M. Robert Dussler

Thomas C. Caskey

Fahim Samaha

Scott E Schwinger

Work History

Title

Chief Financial Officer

Managing Director

Chief Executive Officer

Chief Executive Officer

Chief Financial Officer

Status

Current

Current

Former

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.